Publications of Antje M. Richter

Woods, M. L.; Weiss, A.; Sokol, A. M.; Graumann, J.; Boettger, T.; Richter, A. M.; Schermuly, R. T.; Dammann, R. H.: Epigenetically silenced apoptosis-associated tyrosine kinase (AATK) facilitates a decreased expression of Cyclin D1 and WEE1, phosphorylates TP53 and reduces cell proliferation in a kinase-dependent manner. CANCER GENE THERAPY (2022)

Kuester, M. M.; Schneider, M. A.; Richter, A. M.; Richtmann, S.; Winter, H.; Kriegsmann, M.; Pullamsetti, S. S.; Stiewe, T.; Savai, R.; Muley, T. et al.; Dammann, R. H.: Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. CANCERS 12 (12), 3528 (2020)

Deutschmeyer, V. E.; Richter, A. M.: The ZAR1 protein in cancer; from epigenetic silencing to functional characterisation and epigenetic therapy of tumour suppressors. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 1874 (2), 188417 (2020)

Richter, A. M.; Woods, M. L.; Kuester, M. M.; Walesch, S. K.; Braun, T.; Boettger, T.; Dammann, R. H.: RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice. ONCOGENE 39 (15), pp. 3114 - 3127 (2020)

Deutschmeyer, V.; Breuer, J.; Walesch, S. K.; Sokol, A. M.; Graumann, J.; Bartkuhn, M.; Boettger, T.; Rossbach, O.; Richter, A. M.: Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function. CLINICAL EPIGENETICS 11 (1), 182 (2019)